antiviral

Novartis, Molecular Partners: Ensovibep has the potential to be an important new treatment option in the combat of rapidly evolving SARS-CoV-2 pandemic

Topline results from the randomized EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of ensovibep,…

2 years ago

EIB signs €15.0 million financing deal with AB Science to support the development of masitinib as a treatment for COVID-19

Financing deal worth €15.0 million signed to support clinical development programme for masitinib Masitinib developed as a credible candidate for treating…

3 years ago